Presentation is loading. Please wait.

Presentation is loading. Please wait.

Www.guscairns.com Some questions around efficacy and effectiveness Gus Cairns NAM Publications www.aidsmap.com.

Similar presentations


Presentation on theme: "Www.guscairns.com Some questions around efficacy and effectiveness Gus Cairns NAM Publications www.aidsmap.com."— Presentation transcript:

1 www.guscairns.com Some questions around efficacy and effectiveness Gus Cairns NAM Publications www.aidsmap.com

2 www.guscairns.com Efficacy and effectiveness… Efficacy is intervention use under perfect conditions Efficacy is intervention use under perfect conditions Can be determined for some interventions, eg a vaccine Can be determined for some interventions, eg a vaccine Can’t be (easily) determined where user choice continues to be crucial to effect of intervention, e.g. coitally-dependent interventions Can’t be (easily) determined where user choice continues to be crucial to effect of intervention, e.g. coitally-dependent interventions Effectiveness, in my book, is the actual effect the intervention has in reducing infections in a specific population Effectiveness, in my book, is the actual effect the intervention has in reducing infections in a specific population Very difficult to determine because requires longitudinal measurements of HIV (or STI) incidence – most studies of interventions too small, especially behavioural ones. So we measure risks rather than events. Very difficult to determine because requires longitudinal measurements of HIV (or STI) incidence – most studies of interventions too small, especially behavioural ones. So we measure risks rather than events.

3 www.guscairns.com And something in between… Microbicide, PrEP, condom studies are something in between: effectiveness, but under conditions designed to maximise use of intervention Microbicide, PrEP, condom studies are something in between: effectiveness, but under conditions designed to maximise use of intervention Effectiveness seen may therefore be a maximum: people will probably use it less than in the trial Effectiveness seen may therefore be a maximum: people will probably use it less than in the trial Only likely to underestimate efficacy if trial designed so that ‘standard of care’ offered (ethically necessary) isn’t really standard of care, e.g. free condoms where there were none before. Efficacy in these cases is obscured by adoption of S-O-C Only likely to underestimate efficacy if trial designed so that ‘standard of care’ offered (ethically necessary) isn’t really standard of care, e.g. free condoms where there were none before. Efficacy in these cases is obscured by adoption of S-O-C

4 www.guscairns.com What already happens In UK slightly under 50% of gay men are ‘always’ or consistent condom users In UK slightly under 50% of gay men are ‘always’ or consistent condom users Efficacy of condoms under attempted 100% use = c 85%* Efficacy of condoms under attempted 100% use = c 85%* Effectiveness therefore in the region of 42.5%. Effectiveness therefore in the region of 42.5%. *Davis KR and Weller SC. The Effectiveness of Condoms in Reducing Heterosexual Transmission of HIV. Fam Plann Perspect. 31(6):272-279. 1999.

5 www.guscairns.com Real-world usage

6 www.guscairns.com Influences on condoms… A risk has to be seen as a risk A risk has to be seen as a risk Condom use (and therefore NPTs???) is usually lower in long-term relationships Condom use (and therefore NPTs???) is usually lower in long-term relationships Unprotected sex is not necessarily unsafe sex (serosorting etc) Unprotected sex is not necessarily unsafe sex (serosorting etc) Risk populations change - prevention targets must, too Risk populations change - prevention targets must, too Men can change... Men can change......but women can't always make them...but women can't always make them

7 www.guscairns.com Influences on availability and effectiveness in real world Social position of group to which NPT is offered (stigma etc: do they ‘deserve’ it?) Social position of group to which NPT is offered (stigma etc: do they ‘deserve’ it?) Social desirability or undesirability – am I bad for using this? Social desirability or undesirability – am I bad for using this? Personal desirability or undesirability – is it fun or yucky? Personal desirability or undesirability – is it fun or yucky? Emotional desirability or undesirability – does it imply mistrust/lack of intimacy? Emotional desirability or undesirability – does it imply mistrust/lack of intimacy?

8 www.guscairns.com Influences on availability and effectiveness in real world – part 2 Accurate understanding of NPT effect and efficacy Accurate understanding of NPT effect and efficacy Public or private provision: OTC or prescribed? Public or private provision: OTC or prescribed? Public view of what intervention ‘ought’ to do: Public view of what intervention ‘ought’ to do: ‘Should’ an HIV vaccine be near-100% effective (eg polio, HPV) or is partial efficacy OK? (eg flu) ‘Should’ an HIV vaccine be near-100% effective (eg polio, HPV) or is partial efficacy OK? (eg flu) Should an OTC intervention be more effective (because people are paying for it and there are even more rigorous safety requirements (eg Voltarol)… Should an OTC intervention be more effective (because people are paying for it and there are even more rigorous safety requirements (eg Voltarol)… Or is it OK to be less effective because the state is not paying for it and it’s their choice (eg complementary medicines)? Or is it OK to be less effective because the state is not paying for it and it’s their choice (eg complementary medicines)? COST!! COST!!

9 www.guscairns.com Ethical background Post-trial ethics Post-trial ethics Is HIV these days a sufficiently lethal condition that offering partially-protective NPT is unethical? At what efficacy threshold? Is HIV these days a sufficiently lethal condition that offering partially-protective NPT is unethical? At what efficacy threshold? How you market-describe it: unethical to overstate efficacy, even by implication How you market-describe it: unethical to overstate efficacy, even by implication What if your info is as good as possible but people still misunderstand/misuse it? What if your info is as good as possible but people still misunderstand/misuse it? Because people don’t calculate sexual risk rationally/cognitively Because people don’t calculate sexual risk rationally/cognitively Because it ‘frees’ them to adopt a riskier but more pleasurable behaviour? Because it ‘frees’ them to adopt a riskier but more pleasurable behaviour? Because it damps down demand for safer but more expensive NPTs? Because it damps down demand for safer but more expensive NPTs?

10 www.guscairns.com What will work Has to cause less psychological distress than the thought of not using it (eg vaccine causes very little: condoms cause a significant amount: what would microbicides do?) Has to cause less psychological distress than the thought of not using it (eg vaccine causes very little: condoms cause a significant amount: what would microbicides do?) Social desirability and peer groups Social desirability and peer groups Stigma/bureaucracy met with in requesting intervention (this worries me about PrEP: would happen with anal-specific microbicide too?) Stigma/bureaucracy met with in requesting intervention (this worries me about PrEP: would happen with anal-specific microbicide too?) Powerful influence of individual campaigners Powerful influence of individual campaigners UK PEP story UK PEP story Co-packaging NPTs with risk factors (eg put tenofovir in Viagra!) Co-packaging NPTs with risk factors (eg put tenofovir in Viagra!)


Download ppt "Www.guscairns.com Some questions around efficacy and effectiveness Gus Cairns NAM Publications www.aidsmap.com."

Similar presentations


Ads by Google